Premium
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia
Author(s) -
Advani Anjali S.,
Gundacker Holly M.,
SalaTorra Olga,
Radich Jerald P.,
Lai Raymond,
Slovak Marilyn L.,
Lancet Jeffrey E.,
Coutre Steve E.,
Stuart Robert K.,
Mims Martha P.,
Stiff Patrick J.,
Appelbaum Frederick R.
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08387.x
Subject(s) - clofarabine , medicine , cytarabine , refractory (planetary science) , nucleoside analogue , fludarabine , oncology , regimen , gastroenterology , chemotherapy , nucleoside , biology , biochemistry , astrobiology , cyclophosphamide
Summary Clofarabine and cytarabine target different steps in DNA synthesis and replication, are synergistic in vivo , and have non‐overlapping toxicities, making this combination a potentially promising treatment for acute lymphocytic leukaemia. Thirty‐seven patients were treated. The median age was 41 years, 44% of patients were either in ≥2nd relapse or had refractory disease and 59% of patients had poor risk cytogenetics. Six out of 36 patients (17%) achieved a complete remission with or without complete count recovery; median overall survival was 3 months. Nucleoside transporter expression did not predict outcome. This regimen lacked sufficient activity to warrant further testing.